Subscribe to RSS
DOI: 10.1055/s-2003-38723
© Georg Thieme Verlag Stuttgart · New York
Nuklearmedizinische Diagnostik endokriner Pankreastumoren
Nuclear Medicine Procedures to Diagnose Endocrine Pancreatic TumoursPublication History
Publication Date:
17 April 2003 (online)

Zusammenfassung
Endokrine Pankreastumoren fallen entweder durch ihre typische klinische Symptomatik oder ihren raumfordernden Charakter auf. Mit der Somatostatin-Rezeptorszintigraphie steht ein hochspezifisches und zugleich sensitives Untersuchungsverfahren zur Verfügung, welches abgesehen von inoperablen Lokalbefunden stets in Kombination mit der CT zur Lokalisations- und Ausbreitungsdiagnostik eingesetzt werden sollte. Eine weitere Einsatzmö glichkeit besteht in der Prüfung einer möglichen Radionuklidtherapie (90Y-DOTATOC, 111In-Oktreotid), für die auch die 123I-mIBG Szintigraphie herangezogen werden kann (131I-mIBG). Eine praktische Bedeutung könnte zukünftig auch die PET mit markierten Somatostatin-Analoga oder DOPA-Derivaten erlangen. Zur Optimierung der Lokalisationsdiagnostik ist eine kombiniert morphologisch-funktionelle Untersuchung (PET/CT oder SPECT/low-dose CT) bzw. Bildü berlagerung wünschenswert.
Abstract
The typical clinical features of endocrine pancreatic tumours are either symptoms caused by excessive hormone production or progressive tumour growth. In several prospective studies it has been shown that somatostatin receptor scintigraphy is the most accurate imaging technique currently available to detect endocrine pancreatic tumours. Therefore it should be used whenever curative surgical treatment appears to be feasible. Furthermore it should be applied if a radionuclide treatment of inoperable tumours is considered. In this situation scintigraphy with 123I-mIBG might be useful, too. Future developments include the use of PET with labelled somatostatin analogues or DOPA derivatives as well as image fusion techniques to optimize preoperative tumour localization.
Schlüsselwörter
Endokrine Pankreastumoren - Somatostatin-Rezeptorszintigraphie - mIBG-Szintigraphie - PET - Radionuklidtherapie
Key words
Endocrine pancreatic tumours - somatostatin receptor scintigraphy - mIBG scintigraphy - PET - radionuclide therapy
Literatur
-
1 Kaplan L M. Endocrine tumors of the gastrointestinal tract and pancreas. In: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL (eds) Harrison's principles of internal medicine 13th edition. New York, McGraw-Hill 1994; 1535-1542
-
2 Fraker D L, Jensen R T. Pancreatic endocrine tumors. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer - principles & practice of oncology 5th edition. Philadelphia, New York, Lippincott-Raven 1997; 1678-1704
- 3 Lamberts S WJ, Krenning E P, Reubi J C. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocrine Reviews. 1991; 12 450-482
- 4 Krenning E P, Kwekkeboom D J, Bakker W H, Breeman W A P, Kooij P P M, Oei H Y, van Hagen M, Postema P TE, de Jong M, Reubi J C, Visser T J, Reijs A E M, Hofland L J, Koper J W, Lamberts S W J. Somatostatin receptor scintigraphy with [111In- DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1 000 patients. Eur J Nucl Med. 1993; 20 716-731
- 5 Gibril F, Reynolds J C, Doppman J L, Chen C C, Venzon D J, Termanini B, Weber H C, Stewart C A, Jensen R T. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med. 1996; 125 26-34
- 6 King C M P, Reznek R H, Bomanji J, Ur E, Britton K E, Grossman A B, Besser G M. Imaging neuroendocrine tumors with radiolabelled somatostatin analogues and x-ray: a comparative study. Clin Radiol. 1993; 48 386-391
- 7 Krenning E P, Kooij P PM, Pauwels S, Breeman W A P, Postema P T E, DeHerder W W, Valkema R, Kwekkeboom D J. Somatostatin receptor: scintigraphy and radionuclide therapy. Digestion. 1996; 57 57-61
- 8 Proye C, Malvaux P, Pattou F, Filoche B, Godchaux J M, Maunoury V, Palazzo L, Huglo D, Lefebvre J, Paris J C. Non invasive imaging of insulinomas and gastrinomas with endoscopic ultrasonography and somatostatin receptor scintigraphy. Surgery. 1998; 124 1134-1143
- 9 Hoefnagel C A. Radionuclide therapy revisited. Eur J Nucl Med. 1991; 18 408-431
- 10 Virgolini I, Raderer M, Kurtaran A, Angelberger P, Banyai S, Yang Q, La S, Banyai M, Pidlich J, Niederle B, Scheithauer W, Valent P. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med. 1994; 331 1116-1121
- 11 Ahlström H, Eriksson B, Bergsröm M, Bjurling P, Langström B, Öberg K. Positron emission tomography in endocrine pancreatic tumors. Radiology. 1995; 195 333-337
- 12 Eriksson B, Bergström M, Sundin A, Juhlin C, Örlefors H, Öberg K, Langström B. The role of PET in localization of neuroendocrine and adrenocortical tumors. Ann NY Acad Sci. 2002; 970 159-169
- 13 Adams S, Baum R, Rink T, Schumm-Draeger P M, Usadel K H, Hoer G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med. 1998; 25 79-83
- 14 Lebtahi R, Cadiot G, Sarda L, Daou D, Faraggi M, Petegnief Y, Mignon M, Le Guludec D. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med. 1997; 38 853-858
- 15 Chiti A, Fanti S, Savelli G, Romeo A, Bellanova B, Rodari M, van Graafeiland B J, Monetti N, Bombardieri E. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Eur J Nucl Med. 1998; 25 1396-1403
- 16 Zimmer T, Scherubl H, Faiss S, Stolzel U, Riecken E O, Wiedenmann B. Endoscopic ultrasonography of neuroendocrine tumours. Digestion. 2000; 62 45-50
- 17 Stipa V, Chirletti P, Caronna R. Diagnostic and therapeutic strategy of insulinomas. Chirurgie. 1997; 121 667-671
- 18 Alexander H R, Fraker D L, Norton J A, Bartlett D L, Tio L, Benjamin S B, Doppman J L, Goebel S U, Serrano J, Gibril F, Jensen R T. Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg. 1998; 228 228-238
- 19 Gibril F, Reynolds J C, Chen C C, Yu F, Goebel S U, Serrano J, Doppman J, Jensen R T. Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false positive localizations on management in patients with gastrinomas. J Nucl Med. 1999; 40 539-553
- 20 Termanini B, Gibril F, Reynolds J C, Doppman J L, Chen C C, Stewart C A, Sutliff V E, Jensen R T. Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma on its effect on clinical management. Gastroenterology. 1997; 112 335-347
- 21 Otte A, Jermann E, Behe M, Goetze M, Bucher H C, Roser H W, Heppeler A, Mueller-Brand J, Maecke H R. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med. 1997; 24 792-795
- 22 Hoegerle S, Altehoefer C, Ghanem N, Koehler G, Waller C F, Scheruebl H, Moser E, Nitzsche E. Whole-body 18F Dopa PET for detection of gastrointestinal carcinoid tumors. Radiology. 2001; 220 373-380
Prof. Dr. R. Bares
Universitätsklinikum Tübingen · Radiologische Universitätsklinik · Abteilung und Lehrstuhl für Nuklearmedizin
Röntgenweg 13
72076 Tübingen
Phone: +49/70 71/29-8 21 79
Fax: +49/70 71/29-58 69
Email: bares@uni-tuebingen.de